India, May 26 -- Kura Oncology, Inc. (KURA), a biopharmaceutical company focused on precision medicine for cancer treatment, on Tuesday announced positive results from a phase 1 trial of its next-generation farnesyl transferase inhibitor (FTI), darlifarnib, in combination with adagrasib in heavily pre-treated patients with KRAS G12C-mutated advanced solid tumors. Darlifarnib (KO-2806)
Darlifarnib is an investigational, potent next-generation inhibitor of farnesyl transferase, an enzyme. This drug is particularly designed to manage resistance across multiple targeted therapies by inhibiting RHEB farnesylation, resulting in the sustained blockade of mTORC1 signalling and enhancing RAS-inhibitors anti-tumor activity.
FIT-001 Trial
The phase...